尼群洛尔治疗不同血糖代谢状况的社区原发性轻中度高血压的长期疗效和安全性  

Long-term Efficacy and Safety of Nitrendipine/atenolol Combination Tablets in Community-dwelling Patients with Mild-to-moderate Essential Hypertension by Different Glucose Tolerance Status

作　　者：陈祚[1] 王增武[1] 王馨[1] 郭敏[1] 王文[1] 刘力生[1] Chen Zuo Wang Zengwu Wang Xin et al(Division of Prevention and Com- munity Health, National Center for Cardiovascular Diseases and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ,Beijing 102308, China)

机构地区：[1]中国医学科学院/北京协和医学院阜外医院、国家心血管病中心社区防治部,102308

出　　处：《医学研究杂志》2017年第7期71-74,共4页Journal of Medical Research

基　　金：江苏吉贝尔药业有限公司对本研究的大力支持

摘　　要：目的研究尼群洛尔治疗具有不同血糖代谢状况的社区原发性轻中度高血压的长期疗效和安全性。方法采用多中心、开放设计,单一治疗组的前瞻性设计,征募合格的社区原发性高血压患者2997例,使用尼群洛尔治疗6个月。结果根据患者的血糖代谢情况将患者分为3组,即糖耐量正常组、空腹血糖受损组、糖尿病组。3组患者收缩压分别下降22.7、23.7、22.5mmHg,舒张压分别下降12.4、13.4、12.8mmHg,差异均无统计学意义(P>0.05);总有效率分别为87.8%、90.8%、86.6%(P>0.05),控制率分别为85.9%、92.1%、82.3%(P<0.01)。治疗期间3组分别有5.7%、3.8%、5.7%的患者发生不良反应(P>0.05),多数是轻中度不良反应。结论长期口服尼群洛尔治疗具有不同血糖代谢状况的社区原发性轻中度高血压具有较好的疗效和安全性。Objective To evaluate the long - term efficacy and safety of nitrendipine/atenolol combination tablets in community - dwelling patients with mild - to - moderate essential hypertension by different glucose tolerance status. Methods This is a prospective, muhicenter, open - labeled and single - arm study. A total of 2997 eligible subjects were recruited to receive the nitrendipine/atenolol combination tablets （5mg/10mg） for 6 months. Results The patients were divided into three groups： normal glucose tolerance （ NGT, n = 2311 ） , impaired glucose regulation （ IGR, n = 346） and diabetes （ DM, n = 335 ） according to different glucose tolerance status. Af- ter treatment, diastolic and systolic blood pressures were respectively reduced by 12.4, 13.4 and 12.4mmHg, and by 22.7, 23.7 and 22.5mmHg in NGT, IGR and DM （P 〉 0.05）. The overall effective rates were 87.8% , 90.8% and 86.6% for NGT, IGR and DM, re- spectively. 85.9% , 92.1% and 82.3% of the patients attained their blood pressure goal of below 140/90 mm Hg for three groups, re- spectively. The change were significant different in triglycerlde and fasting blood glucose levels for three groups. The incidence of adverse drug reactions was 5.7% , 3.8% and 5.7% （P 〉 0.05）. Conclusion Our results suggest that the nitrendipine/atenolol combination tablets were effective and safe for the treatment of community - dwelling patients with mild to moderate essential hypertension by different glucose tolerance status.

关 键 词：原发性高血压 尼群洛尔 疗效 糖尿病 空腹血糖受损 

分 类 号：R5[医药卫生—内科学]